Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus R-CHOP in untreated MYC/BCL2 double-expressor DLBCL
CTR20192684Phase 3Completed
- Sponsor
- Chipscreen Biosciences
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Chipscreen Biosciences. Started May 2020; status: completed.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20192684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192684.